Dolomite and ClearBridge develop ClearCell instrument

Detects circulating tumour cells and paves the way for personalised cancer treatment

The ClearCell system can isolate, enumerate and retrieve wholly intact and viable Circulating Tumour Cells (CTCs) from whole blood

UK-based microfluidics expert Dolomite has collaborated with Clearbridge BioMedics of Singapore in the development of an instrument that is able to detect and isolate Circulating Tumour Cells (CTCs) from small quantities of whole, unprocessed blood.

The ClearCell system can isolate, enumerate and retrieve wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of application areas including molecule analysis, cancer diagnostics and cancer treatment decisions, this instrument also paves the way for personalised cancer medication for patients, says Dolomite.

Andrew Lovatt, chief executive of Dolomite, says: ‘By combining the cutting edge scientific research of Clearbridge BioMedics and National University of Singapore with the proven track record in product development of Dolomite, both companies have leveraged their expertise to gain early traction in the novel field of automated capture of viable CTCs. We are looking forward to extending our partnership beyond research tools and into the clinical diagnostic domain.’

Johnson Chen, md of Clearbridge BioMedics, added: ‘We see microfluidics playing an increasing key role in many companion diagnostics and in-vitro diagnostics devices. Dolomite has demonstrated that it is a leader in this field, and we look forward to developing our future platform devices and systems together.’

Companies